Nanoparticle‐Based Drug Delivery for Therapy of Lung Cancer: Progress and Challenges

The last decade has witnessed enormous advances in the development and application of nanotechnology in cancer detection, diagnosis, and therapy culminating in the development of the nascent field of “cancer nanomedicine.” A nanoparticle as per the National Institutes of Health (NIH) guidelines is any material that is used in the formulation of a drug resulting in a final product smaller than 1 micron in size. Nanoparticle‐based therapeutic systems have gained immense popularity due to their ability to overcome biological barriers, effectively deliver hydrophobic therapies, and preferentially target disease sites. Currently, many formulations of nanocarriers are utilized including lipid‐based, polymeric and branched polymeric, metal‐based, magnetic, and mesoporous silica. Innovative strategies have been employed to exploit the multicomponent, three‐dimensional constructs imparting multifunctional capabilities. Engineering such designs allows simultaneous drug delivery of chemotherapeutics and anticancer gene therapies to site‐specific targets. In lung cancer, nanoparticle‐based therapeutics is paving the way in the diagnosis, imaging, screening, and treatment of primary and metastatic tumors. However, translating such advances from the bench to the bedside has been severely hampered by challenges encountered in the areas of pharmacology, toxicology, immunology, large‐scale manufacturing, and regulatory issues. This review summarizes current progress and challenges in nanoparticle‐based drug delivery systems, citing recent examples targeted at lung cancer treatment.